千草脑脉通口服液治疗急性缺血性卒中90例临床研究

Clinical Study on Qiancao Naomaitong Oral Liquid for Acute Ischemic Stroke of 90 Cases

目的:评价千草脑脉通口服液治疗急性缺血性卒中的临床疗效和安全性。方法:急性缺血性卒中患者180例随机分为治疗组与对照组,每组90例,对照组进行常规治疗,治疗组在常规治疗的同时加服千草脑脉通口服液。治疗2周及4周后,采用神经功能缺损程度评分、日常生活活动能力(ADL)评分、简易智力状态量表(MMSE)评分、美国国立精神卫生研究所流行病学研究中心抑郁量表(CES-D)评分评价两组的临床疗效。每组各选取40例患者进行治疗前和治疗4周后的血液流变学检查。结果:治疗4周后,治疗组有效率明显高于对照组(P<0.05);治疗组MMSE评分较治疗前明显增加(P<0.05),CES-D评分、血小板聚集率、血浆比黏度和纤维蛋白原较治疗前明显降低(P<0.05);治疗组ADL受损率较本组治疗前及对照组明显减少(P<0.05)。结论:千草脑脉通口服液治疗急性缺血性卒中在减少患者神经功能缺损积分的同时可改善认知功能和情感状况,使患者日常生活能力进一步提高,并可改善血液流变学指标。

Objective： To evaluate the therapeutic effect and safety of Qiancao Naomaitong Oral Liquid for acute ischemic stroke. Methods： 180 cases of acute ischemic stroke were randomly divided into treatment group （n= 90） and control group （n= 90）. Routine treatment was used in the control group, while Qiancao Naomaitong Oral Liquid was added in the treatment group. The therapeutic effect was evaluated by neurologic deficit score （NDS）, activities of daily living （ADL）, mini-mental state examination （MMSE） and center for epidemiological survey depression scale （CES-D） after 2 and 4 weeks of treatment respectively. Hemorheologic test was conducted on 40 patients in each group before and after 4 weeks of treatment. Results： After 4 weeks of treatment, the efficiency of treatment group was significantly higher than that of control group（P〈0.05）; MMSE scores increased significantly, while platelet aggregation rate, plasma viscosity and fibrinogen decreased significantly in the treatment group （P〈0. 05） ; impaired rate of ADL decreased significantly in the treatment group and was lower than that in the control group as well （P〈0. 05）. Conclusion： Qiancao Naomaitong Oral Liquid can reduce NDS, improve cognitive function, daily living ability, emotional state and hemorheologic indexes for acute ischemic stroke.